<DOC>
	<DOCNO>NCT02626000</DOCNO>
	<brief_summary>A Phase 1b/3 Multicenter , Randomized , Trial Talimogene Laherparepvec Combination With Pembrolizumab Treatment Subjects Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_summary>
	<brief_title>Talimogene Laherparepvec With Pembrolizumab Recurrent Metastatic Squamous Cell Carcinoma Head Neck ( MASTERKEY232 / KEYNOTE-137 )</brief_title>
	<detailed_description>This phase 1b/3 , multicenter , clinical trial . The study conduct 2 part ( phase 1b phase 3 ) . In phase 1b talimogene laherparepvec administer combination pembrolizumab approximately 40 subject recurrent metastatic SCCHN . DLT evaluate base first 18 DLT-evaluable subject . An expansion cohort additional 22 treated subject enrol evaluate safety estimate efficacy combination talimogene laherparepvec pembrolizumab support decision initiate phase 3 study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion Criteria Male female age ≥ 18 year time inform consent Histologically confirm diagnosis metastatic recurrent SCCHN oral cavity , oropharynx , hypopharynx , larynx . Disease must unsuitable curative surgical resection must amenable curative radiotherapy . Disease must progress treatment platinumcontaining regimen define one following : i. disease progression recurrence 3 6 month prior curatively intend multimodal therapy ( include platinum therapy ) locoregionally advanced SCCHN . ii . disease progression recurrence prior platinum therapy recurrent metastatic set Note : This criterion applicable subject treatment recurrent/metastatic setting Subject must candidate intralesional therapy administration define one following : i. least 1 injectable cutaneous , subcutaneous , nodal SCCHN tumor ≥ 10 mm long diameter ii . multiple injectable cutaneous , subcutaneous , nodal SCCHN tumor aggregate long diameter ≥ 10 mm Note : Mucosal surface tumor lesion visceral metastasis inject . ECOG performance status 0 1 Adequate organ function determine within 14 day prior enrollment Female subject childbearing potential must negative pregnancy test within 72 hour prior enrollment . Other Inclusion Criteria May Apply Exclusion Criteria Has know active CNS metastasis and/or carcinomatous meningitis . Primary nasopharyngeal carcinoma . Subject risk airway compromise event postinjection tumor swelling/inflammation base investigator judgment . Phase 3 : Previous treatment 3 systemic regimen give recurrent and/or metastatic disease History malignancy within past 3 year History interstitial lung disease ( ILD ) . Prior therapy talimogene laherparepvec , pembrolizumab , antiPD1 , antibody drug specifically target Tcell costimulation immune check point pathway . History evidence active autoimmune disease require systemic treatment past 2 year ( ie , use disease modify agent , corticosteroid immunosuppressive drug ) . Evidence clinically significant immunosuppression Active herpetic skin lesion prior complication herpetic infection ( eg , herpetic keratitis encephalitis ) . Requires intermittent chronic treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use . Prior chemotherapy , radiotherapy , biological cancer therapy , target therapy , major surgery within 28 day prior enrollment recover CTCAE grade 1 good adverse event due cancer therapy administer 28 day prior enrollment . Expected require cancer therapy study exception local palliative radiation treatment site bone metastasis . Known human immunodeficiency virus ( HIV ) disease . Has acute chronic active hepatitis B virus hepatitis C virus infection receive treatment nucleotide analog use treatment hepatitis B virus ( eg , lamivudine , adefovir , tenofovir , telbivudine , entecavir ) , ribavirin , interferon alpha within 12 week initiation study treatment . Received live vaccine within 28 day prior enrollment . Subject pregnant breastfeeding , expect conceive father child within duration trial Female subject childbearing potential male subject reproductive potential unwilling use acceptable method ( ) effective contraception study treatment 3 month last dose talimogene laherparepvec/placebo 4 month last dose pembrolizumab , whichever later . Sexually active subject partner unwilling use male female latex condom avoid potential viral transmission sexual contact treatment within 30 day treatment talimogene laherparepvec/placebo . Subject unwilling minimize exposure his/her blood body fluids individual higher risk HSV1 induce complication ( eg , immunosuppressed individual , HIVpositive individual , pregnant woman , child age 1 year ) talimogene laherparepvec treatment 30 day last dose talimogene laherparepvec Has history ( noninfectious ) pneumonitis require steriods current pneumonitis Subjects tumor directly contact encases major blood vessel AND ulceration and/or fungation onto skin surface Subject undergone reirradiation Other Exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Recurrent Metastatic Squamous Cell Carcinoma Head Neck</keyword>
</DOC>